1368 Results for "

prostates

" in MedChemExpress (MCE) Product Catalog:

Products (1368)

Sort by :

Categories

By Targets

Products

246

Enzalutamide

246 Publications Verification

Cat. No.: HY-70002

CAS No.: 915087-33-1

Synonyms: MDV3100

Target:

Androgen Receptor Autophagy

Research Areas:

Cancer

Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

202

Doxycycline monohydrate

202 Cited Publications

Cat. No.: HY-W008923

CAS No.: 17086-28-1

Target:

MMP Parasite Bacterial Antibiotic Apoptosis Akt PI3K

Research Areas:

Infection Neurological Disease Inflammation/Immunology Cancer

Doxycycline monohydrate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline monohydrate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline monohydrate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline monohydrate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline monohydrate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline monohydrate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

122

PX-478

122 Cited Publications

Cat. No.: HY-10231

CAS No.: 685898-44-6

Purity: ≥98.0%

Target:

HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy

Research Areas:

Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer

PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

C75

54 Cited Publications

Cat. No.: HY-12364

CAS No.: 218137-86-1

Purity: 99.91%

Target:

Carnitine Palmitoyltransferase (CPT) Fatty Acid Synthase (FASN)

Research Areas:

Cancer

C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM . C75 is a potent CPT1A activator .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Rucaparib

53 Cited Publications

Cat. No.: HY-10617A

CAS No.: 283173-50-2

Purity: 99.97%

Synonyms: AG014699; PF-01367338

Target:

PARP

Research Areas:

Cancer

Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Rucaparib phosphate

52 Cited Publications

Cat. No.: HY-10617

CAS No.: 459868-92-9

Purity: 99.56%

Synonyms: AG-014699 phosphate; PF-01367338 phosphate

Target:

PARP

Research Areas:

Cancer

Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Rucaparib monocamsylate

43 Cited Publications

Cat. No.: HY-102003

CAS No.: 1859053-21-6

Purity: 99.82%

Synonyms: AG014699 monocamsylate; PF-01367338 monocamsylate

Target:

PARP

Research Areas:

Cancer

Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

2-Methoxyestradiol

34 Cited Publications

Cat. No.: HY-12033

CAS No.: 362-07-2

Purity: 99.76%

Synonyms: 2-ME2; NSC-659853

Category:

Monophenols Disease markers Endocrine diseases Phenols Endogenous metabolite Disease Research Fields Cancer Steroids

Target:

Endogenous Metabolite Microtubule/Tubulin HIF/HIF Prolyl-Hydroxylase Cytochrome P450 JNK Caspase Estrogen Receptor/ERR Reactive Oxygen Species (ROS) Apoptosis Autophagy

2-Methoxyestradiol (2-ME2; NSC-659853) is an endogenous steroid metabolite generated from 17β-estradiol, possessing various activities such as antitumor and antiangiogenic effects. 2-Methoxyestradiol competitively binds to the colchicine-binding site of tubulin (tubulin), interfering with microtubule assembly dynamics. 2-Methoxyestradiol inhibits CYP1A1/CYP1B1, HIF-1α/2α, and superoxide dismutase, activates the JNK signaling pathway, elevates ROS levels, and induces cell cycle arrest and apoptosis (apoptosis). 2-Methoxyestradiol is used in cancer-related research, such as breast cancer, prostate cancer, and multiple myeloma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

PF-562271

32 Cited Publications

Cat. No.: HY-10459

CAS No.: 717907-75-0

Purity: 99.68%

Synonyms: VS-6062

Target:

FAK Pyk2

PF-562271 (VS-6062) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC₅₀ of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

PF-562271 (besylate)

32 Cited Publications

Cat. No.: HY-10458

CAS No.: 939791-38-5

Purity: 99.17%

Synonyms: VS-6062 (besylate)

Target:

FAK Pyk2

PF-562271 besylate (VS-6062 besylate) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC₅₀ of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 besylate induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 besylate exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 besylate reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 besylate can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

ARV-771

30 Cited Publications

Cat. No.: HY-100972

CAS No.: 1949837-12-0

Purity: 98.87%

Target:

PROTACs Epigenetic Reader Domain Apoptosis Ferroptosis c-Myc Androgen Receptor

Research Areas:

Cancer

ARV-771 is a BET PROTAC degrader, with K_d values of 34, 4.7, 8.3, 7.6, 9.6 and 7.6 nM against BRD2 (1), BRD2 (2), BRD3 (1), BRD3 (2), BRD4 (1) and BRD4 (2) , respectively. ARV-771 inhibits the transcription of AR/AR-v7 and its downstream target genes. By degrading BRD4 protein, ARV-771 enhances the sensitivity of prostate cancer cells to ferroptosis, suppresses cancer cell viability, and induces apoptosis. ARV-771 downregulates the levels of BRD4, c-MYC and AR-V7 in tumor tissues and inhibits tumor tissue growth. ARV-771 can be used in prostate cancer-related research .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

PF-562271 hydrochloride

30 Cited Publications

Cat. No.: HY-20403

CAS No.: 939791-41-0

Synonyms: VS-6062hydrochloride

Target:

FAK Pyk2

PF-562271 hydrochloride (VS-6062 hydrochloride) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC₅₀ of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 hydrochloride induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 hydrochloride exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 hydrochloride reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 hydrochloride can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant

30 Cited Publications

Cat. No.: HY-Y1883

CAS No.: 9002-93-1

Target:

Biochemical Assay Reagents Apoptosis

Research Areas:

Infection Cancer

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Polyethylene glycol mono(4-tert-octylphenyl) ether

30 Cited Publications

Cat. No.: HY-Y1883A

CAS No.: 9002-93-1

Target:

Biochemical Assay Reagents

Research Areas:

Infection Cancer

Polyethylene glycol mono(4-tert-octylphenyl) ether is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV .

Compare